{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:02Z","timestamp":1791389882080,"version":"4.3.3"},"reference-count":134,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH065"],"award-info":[{"award-number":["ZR2023MH065"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbcan.2025.189445","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:11:04Z","timestamp":1757095864000},"page":"189445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The evolving landscape of antibody-drug conjugates in small cell lung cancer: From research progress to clinical application"],"prefix":"10.1016","volume":"1880","author":[{"given":"Haoyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189445_bb0010","first-page":"620","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189445_bb0015","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.bbcan.2025.189445_bb0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2025.189445_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189445_bb0035","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189445_bb0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189445_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12672-024-01171-1","article-title":"Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research","volume":"15","author":"Meng","year":"2024","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-024-00784-7","article-title":"Assessment of targets of antibody drug conjugates in SCLC","volume":"9","author":"Ajay","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"302","key":"10.1016\/j.bbcan.2025.189445_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of Rovalpituzumab Tesirine compared with Topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03","author":"Dowlati","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189445_bb0075","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189445_bb0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10200","key":"10.1016\/j.bbcan.2025.189445_bb0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/13543776.2023.2291390","article-title":"Development of tubulin polymerization inhibitors as anticancer agents","volume":"33","author":"Peerzada","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189445_bb0105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/med.21568","article-title":"Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy","volume":"39","author":"Arnst","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189445_bb0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig. New Drugs"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189445_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2011.03.017","article-title":"Antibody-DM1 conjugates as cancer therapeutics","volume":"307","author":"Lopus","year":"2011","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189445_bb0125","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jacsau.2c00448","article-title":"40 years of Duocarmycins: a graphical structure\/function review of their chemical evolution, from SAR to prodrugs and ADCs","volume":"2","author":"Felber","year":"2022","journal-title":"JACS Au"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189445_bb0130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.drudis.2020.11.020","article-title":"How can the potential of the duocarmycins be unlocked for cancer therapy?","volume":"26","author":"Jukes","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189445_bb0135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/med.20212","article-title":"Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines","volume":"32","author":"Gerratana","year":"2012","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189445_bb0140","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.2023022822","article-title":"Old rivals become new friends","volume":"143","author":"Rousselot","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189445_bb0145","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","article-title":"New life of topoisomerase I inhibitors as antibody-drug conjugate warheads","volume":"29","author":"Pommier","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189445_bb0150","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/17460441.2022.2055545","article-title":"The design and discovery of topoisomerase I inhibitors as anticancer therapies","volume":"17","author":"Mart\u00edn-Encinas","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548292","article-title":"ADCC: the rock band led by therapeutic antibodies, tumor and immune cells","volume":"16","author":"Vincken","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl9171","article-title":"Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy","volume":"8","author":"Cao","year":"2022","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189445_bb0185","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40259-023-00618-1","article-title":"Unlocking the power of complement-dependent cytotoxicity: engineering strategies for the development of potent therapeutic antibodies for cancer treatments","volume":"37","author":"Lee","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.bbcan.2025.189445_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2025.189445_bb0195","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189445_bb0200","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bbcan.2025.189445_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189445_bb0210","article-title":"Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bbcan.2025.189445_bb0215","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189445_bb0220","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","article-title":"Improved lysosomal trafficking can modulate the potency of antibody drug conjugates","volume":"28","author":"DeVay","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbcan.2025.189445_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-A necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189445_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189445_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202306309","article-title":"Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Adv. Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0245","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189445_bb0250","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189445_bb0255","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114248","article-title":"Targeting the notch signaling pathway and the notch ligand, DLL3, in small cell lung cancer","volume":"159","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0270","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: implications for therapy","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0280","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jtho.2021.07.012","article-title":"All that glitters is not gold: the story of Rovalpituzumab Tesirine in SCLC","volume":"16","author":"Uprety","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189445_bb0290","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of Rovalpituzumab Tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung Cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0295","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab Tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study","volume":"16","author":"Johnson","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104524","article-title":"DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: a narrative review","volume":"204","author":"Peddio","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189445_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105603","article-title":"DLL3 regulates notch signaling in small cell lung cancer","volume":"25","author":"Kim","year":"2022","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189445_bb0310","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/1535-7163.MCT-21-0693","article-title":"Comparison of Pyrrolobenzodiazepine dimer Bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, antibody-drug conjugate efficacy and toxicity","volume":"22","author":"Tiberghien","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100883","article-title":"Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression","volume":"14","author":"Vitorino","year":"2021","journal-title":"Transl. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0320","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jtho.2021.02.022","article-title":"A phase 1-2 study of Rovalpituzumab Tesirine in combination with Nivolumab plus or minus Ipilimumab in patients with previously treated extensive-stage SCLC","volume":"16","author":"Malhotra","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0325","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12967-024-05568-y","article-title":"DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models","volume":"22","author":"Lin","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189445_bb0330","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2020.04.017","article-title":"SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study","volume":"145","author":"Morgensztern","year":"2020","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189445_bb0335","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1535-7163.MCT-23-0701","article-title":"FZ-AD005, a novel DLL3-targeted antibody-drug conjugate with topoisomerase I inhibitor, shows potent antitumor activity in preclinical models","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189445_bb0340","series-title":"Presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), Barcelona, Spain","article-title":"Preliminary results from a phase 1a\/1b, open-label, multicenter study of ZL-1310, a DLL3-targeted ADC, to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer","author":"Spira","year":"2024"},{"key":"10.1016\/j.bbcan.2025.189445_bb0345","doi-asserted-by":"crossref","unstructured":"M. R. Patel, Y. L. Wu, Z. Wang, and et al., \"ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update,\" in 2025 ASCO Annual Meeting, 2025\/06\/02 2025, vol. 43, suppl 16 ed., p. 3041, doi: https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3041.","DOI":"10.1200\/JCO.2025.43.16_suppl.3041"},{"key":"10.1016\/j.bbcan.2025.189445_bb0350","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0355","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189445_bb0360","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189445_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189445_bb0370","series-title":"Presented at the IASLC 2024 World Conference on Lung Cancer (WCLC 2024), San Diego, California, USA","article-title":"Ifinatamab Deruxtecan (I-DXd) in extensive-stage small cell lung Cancer (ES-SCLC): Interim analysis of IDeate-Lung01","author":"Rudin","year":"2024"},{"key":"10.1016\/j.bbcan.2025.189445_bb0375","series-title":"Presented at the IASLC 2024 World Conference on Lung Cancer (WCLC 2024), San Diego, California, USA","article-title":"Efficacy and safety of HS-20093 in extensive-stage small cell lung cancer (ES-SCLC): A multicenter phase I study (ARTEMIS-001)","author":"Wang","year":"2024"},{"key":"10.1016\/j.bbcan.2025.189445_bb0380","series-title":"Presented at the ESMO Asia Congress 2024, Singapore","article-title":"A phase I\/II multicenter, first-in-human study of DB-1311\/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors","author":"Cheng","year":"2024"},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2025.189445_bb0385","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2024.42.16_suppl.3012","article-title":"Results of a phase 1\/2 study of MHB088C: a novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors","volume":"42","author":"Shen","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0390","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0395","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0400","series-title":"Presented at the IASLC 2024 World Conference on Lung Cancer (WCLC 2024), San Diego, California, USA","article-title":"SHR-A1921: A TROP-2 targeted antibody-drug conjugate (ADC) in patients with advanced small-cell lung Cancer (SCLC)","author":"Wang","year":"2024"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189445_bb0405","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1158\/1078-0432.CCR-24-1547","article-title":"A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer","volume":"30","author":"Morgensztern","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2025.189445_bb0410","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2024.42.16_suppl.3001","article-title":"First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","volume":"42","author":"Chandana","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189445_bb0415","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189445_bb0420","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: a dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189445_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101874","article-title":"High expression of B7-H3 on monocyte\/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis","volume":"41","author":"Zhang","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0430","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189445_bb0435","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189445_bb0440","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab Deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bbcan.2025.189445_bb0445","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189445_bb0450","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/procel\/pwaf002","article-title":"The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts","volume":"16","author":"Liu","year":"2025","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbcan.2025.189445_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189445_bb0460","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189445_bb0465","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189445_bb0470","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","article-title":"Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung Cancer","volume":"28","author":"Jin","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189445_bb0475","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","article-title":"Overcoming chemotherapy resistance in SCLC","volume":"16","author":"Herzog","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8005","key":"10.1016\/j.bbcan.2025.189445_bb0480","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","article-title":"Evolutionary trajectories of small cell lung cancer under therapy","volume":"627","author":"George","year":"2024","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bbcan.2025.189445_bb0485","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189445_bb0490","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.21.01639","article-title":"Radiation and systemic therapy for limited-stage small-cell lung cancer","volume":"40","author":"Bogart","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0495","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00054-2020","article-title":"Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry","volume":"6","author":"Moor","year":"2020","journal-title":"ERJ Open Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0500","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-2600(22)00228-4","article-title":"Home monitoring in interstitial lung diseases","volume":"11","author":"Wijsenbeek","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189445_bb0505","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0510","first-page":"98","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer, NPJ","volume":"8","author":"Rugo","year":"2022","journal-title":"Breast Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189445_bb0515","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189445_bb0520","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","article-title":"Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG partners foundation","volume":"35","author":"Peters","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189445_bb0525","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189445_bb0530","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189445_bb0540","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2020.1796","article-title":"Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial","volume":"6","author":"Cort\u00e9s","year":"2020","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189445_bb0545","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting replication stress and chemotherapy resistance with a combination of Sacituzumab Govitecan and Berzosertib: a phase I clinical trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189445_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189445_bb0555","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0560","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lungcan.2019.06.025","article-title":"Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment","volume":"135","author":"Messaritakis","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189445_bb0565","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtcvs.2020.10.148","article-title":"Predictors of survival following surgical resection of limited-stage small cell lung cancer","volume":"161","author":"Zhou","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189445_bb0570","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?","volume":"203","author":"Fu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2025.189445_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061228","article-title":"The role of toll-like receptor agonists and their nanomedicines for tumor immunotherapy","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189445_bb0585","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41568-025-00803-0","article-title":"Challenges of small cell lung cancer heterogeneity and phenotypic plasticity","volume":"25","author":"Simpson","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0590","first-page":"18","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Can."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189445_bb0595","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1535-7163.MCT-21-0193","article-title":"Nonclinical efficacy and safety of CX-2029, an anti-CD71 Probody-drug conjugate","volume":"21","author":"Singh","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189445_bb0600","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0605","series-title":"Presented at the 2025 ASCO Annual Meeting, Chicago, IL, USA","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR \u00d7 HER3 bispecific ADC, in patients with locally advanced or metastatic SCLC","author":"Huang","year":"2025"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0610","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","article-title":"Antibody-drug conjugates in breast cancer: current evidence and future directions","volume":"14","author":"Li","year":"2025","journal-title":"Exp Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189445_bb0615","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189445_bb0620","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189445_bb0625","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189445_bb0630","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02744","article-title":"Patritumab Deruxtecan (HER3-DXd; MK-1022) in non-small cell lung cancer after platinum-based chemotherapy and immunotherapy","author":"Steuer","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189445_bb0635","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189445_bb0640","unstructured":"\"TROPION-Lung02: Datopotamab deruxtecan with pembrolizumab \u00b1 platinum chemotherapy as first-line treatment for advanced\/metastatic non\u2013small cell lung cancer,\" in 2025 ASCO Annual Meeting, Chicago, IL, USA, 20250601 2025: American Society of Clinical Oncology. https:\/\/doi.org\/10.1200\/JCO.2025.xx.xxxx. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2025.xx.xxxx."},{"key":"10.1016\/j.bbcan.2025.189445_bb0645","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","author":"Cascone","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0650","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189445_bb0655","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","article-title":"Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer","volume":"39","author":"Chan","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189445_bb0660","first-page":"423","article-title":"Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer","volume":"1","author":"Stewart","year":"2020","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189445_bb0665","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","article-title":"Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies","volume":"187","author":"Liu","year":"2024","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189445_bb0670","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:26:42Z","timestamp":1781065602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":134,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0304419X25001878"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189445","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of antibody-drug conjugates in small cell lung cancer: From research progress to clinical application","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189445"}}